Friberg, L.E.

irinotecan patient cancer pharmacokinetic sn -38 clearance -38 treatment cyp 3a ugt 1a midazolam study sn -38g effect smoking smoker metabolite diarrhea variant genotype group signi verweij j analysis toxicity activity range erythromycin breath test allele variability metabolism irinotecan clearance midazolam clearance erythromycin parameter table extent signi ficantly oncol polymorphism dosing cyp 3a activity haplotype minute abcc 2 exposure concentration nonsmokers transporter mathijssen ugt 1a genotype midazolam clearance test article cytochrome plasma grade sparreboom number association equation breath glucuronidation irinotecan treatment mathijssen rh ratio cancer institute curve frequency january cigarette 350 mg /m abcc 2*2 haplotype bruijn p pharmacol verweij american cyp 3a phenotype ugt 1a allele probe blood